-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 2,852.6%
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 2,852.6%
Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 112,200 shares, an increase of 2,852.6% from the November 30th total of 3,800 shares. Based on an average daily volume of 556,700 shares, the short-interest ratio is presently 0.2 days. Approximately 1.3% of the company's stock are sold short.
Allarity Therapeutics Price Performance
Shares of Allarity Therapeutics stock traded down $0.01 during trading on Wednesday, hitting $0.22. 7,272 shares of the company's stock traded hands, compared to its average volume of 1,628,587. Allarity Therapeutics has a 1 year low of $0.22 and a 1 year high of $12.86. The business has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.97. The company has a current ratio of 0.47, a quick ratio of 0.47 and a debt-to-equity ratio of 0.73.
Get Allarity Therapeutics alerts:Allarity Therapeutics (NASDAQ:ALLR – Get Rating) last released its quarterly earnings data on Friday, October 7th. The company reported ($0.72) earnings per share for the quarter. As a group, sell-side analysts anticipate that Allarity Therapeutics will post -1.62 earnings per share for the current year.
Institutional Trading of Allarity Therapeutics
An institutional investor recently bought a new position in Allarity Therapeutics stock. Renaissance Technologies LLC purchased a new stake in shares of Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 114,227 shares of the company's stock, valued at approximately $233,000. Institutional investors and hedge funds own 1.61% of the company's stock.About Allarity Therapeutics
(Get Rating)
Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
Read More
- Get a free copy of the StockNews.com research report on Allarity Therapeutics (ALLR)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Why Did Immutep Ltd Stock Soar Recently?
- Yum! Brands Looks Tasty in 2023
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Rating) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 112,200 shares, an increase of 2,852.6% from the November 30th total of 3,800 shares. Based on an average daily volume of 556,700 shares, the short-interest ratio is presently 0.2 days. Approximately 1.3% of the company's stock are sold short.
全能治療公司(NASDAQ:ALLR-獲取評級)是十二月份短期興趣大幅增加的目標。截至十二月十五日,共有 112,200 股短期權益,較十一月三十日共 3,800 股股份增加 2,852.6%。根據每日平均成交量為 556,700 股,短息比率目前為 0.2 天。約 1.3% 的公司股票賣空。
Allarity Therapeutics Price Performance
全面治療價格表現
Shares of Allarity Therapeutics stock traded down $0.01 during trading on Wednesday, hitting $0.22. 7,272 shares of the company's stock traded hands, compared to its average volume of 1,628,587. Allarity Therapeutics has a 1 year low of $0.22 and a 1 year high of $12.86. The business has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.97. The company has a current ratio of 0.47, a quick ratio of 0.47 and a debt-to-equity ratio of 0.73.
周三交易期間,全能治療股的股價下跌 0.01 美元,觸及 0.22 美元。該公司股票交易手中的 7,272 股,而其平均交易量為 1,628,587。極度治療有一個 1 年低點 0.22 美元和 1 年高點 12.86 美元。該公司擁有 50 天的簡單移動平均線 0.47 美元,以及 200 天的簡單移動平均線 0.97 美元。該公司的流動比率為 0.47,快速比率為 0.47,債務與權益比率為 0.73。
Allarity Therapeutics (NASDAQ:ALLR – Get Rating) last released its quarterly earnings data on Friday, October 7th. The company reported ($0.72) earnings per share for the quarter. As a group, sell-side analysts anticipate that Allarity Therapeutics will post -1.62 earnings per share for the current year.
極度治療(NASDAQ:ALLR-獲取評級)最近一次發布了其季度收益數據,週五,10 月 7 日。該公司報告了該季度每股盈利(0.72 美元)。作為一個集團,賣方分析師預計,全面治療將在本年度發布 -1.62 的每股收益。
Institutional Trading of Allarity Therapeutics
傾向治療的機構交易
About Allarity Therapeutics
關於極度治療
(Get Rating)
(取得評分)
Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
Allarity Theraptics, Inc 是一家臨床階段生物製藥公司,致力於使用其藥物反應預測技術產生的特定藥物伴侶診斷開發腫瘤治療。其候選藥物包括 Stenoparib,一種用於治療腎細胞癌的 2 期臨床試驗中的 Poly-ADP-核糖聚合酶抑製劑;多維替尼(Dovitinib),用於治療腎細胞癌的泛酪氨酸激酶抑製劑;IXEMPRA 是用於治療轉移性乳腺癌的微管抑製劑;利普拉斯(Liplacis),用於治療腎細胞癌的微管抑制劑 IXEMPRA 2 項轉移性乳腺癌臨床試驗;以及 2X-111,一種多柔比星的脂質體配方,處於轉移性乳腺癌和多形性膠質母細胞瘤的 2 期臨床試驗中。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Allarity Therapeutics (ALLR)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Why Did Immutep Ltd Stock Soar Recently?
- Yum! Brands Looks Tasty in 2023
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- 免費獲得全面治療研究報告
- 前三名股票分析師說購買
- 迪克的體育用品股票可以在第四季度獲得另一個勝利嗎?
- 為什麼 Immutep 有限公司股票最近飆升?
- 百勝!品牌在 2023 年看起來很美味
- 3 種工業股票可幫助建立您的 2023 觀察列表
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收全面治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊獲取有關 Allarity 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧